1,659
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Bioactive metabolites from the leaves of Withania adpressa

, , ORCID Icon, , , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 505-510 | Received 16 May 2018, Accepted 08 Jul 2018, Published online: 17 Nov 2018

References

  • Abdeljebbar LH, Humam M, Christen P, Jeannerat D, Vitorge B, Amzazi S, Benjouad A, Hostettmann K, Bekkouche K. 2007. Withanolides from Withania adpressa. Helv Chim Acta. 90:346–352.
  • Abdeljebbar LH, Benjouad A, Morjani H, Merghoub N, El Haddar S, Humam M, Christen P, Hostettmann K, Bekkouche K, Amzazi S. 2009. Antiproliferative effects of withanolides from Withania adpressa. Therapie. 64:121–127.
  • Aggarwal BB. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell. 6:203–208.
  • Aggarwal BB, Sung B. 2011. NF-κB in cancer: a matter of life and death. Cancer Discov. 1:469–471.
  • Atta-ur-Rahman A-R, Yousaf M, Gul W, Qureshi S, Choudhary MI, Voelter W, Hoff A, Jens F, Naz A. 1998. Five new withanolides from Withania coagulans. Heterocycles. 48:1801–1811.
  • Bellakhdar J. 1997. La Pharmacopée marocaine traditionnelle, médicine arabe ancienne et savoirs. Paris: Ibis Press.
  • Bhattacharya SK, Satyan KS, Ghosal S. 1997. Antioxidant activity of glycowithanolides from Withania somnifera. Indian J Exp Biol. 35:236–239.
  • Bhattacharya A, Ghosal S, Bhattacharya SK. 2001. Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol. 74:1–6.
  • Choudhary MI, Nawaz SA, Zaheer-ul-Haq LMA, Ghayur MN, Jalil S, Riaz N, Yousuf S, Malik A, Gilani AH, Atta-ur-Rahman A-R. 2005. Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys Res Commun. 334:276–287.
  • Cordero CP, Morantes SJ, Páez A, Rincón J, Aristizábal FA. 2009. Cytotoxicity of withanolides isolated from Acnistus arborescens. Fitoterapia. 80:364–368.
  • De Sousa EA, da Silva AA, Cavalheiro AJ, Lago JHG, Chaves MH. 2014. A new flavonoid derivative from leaves of Oxandra sessiliflora. J Braz Chem Soc. 25:704–708.
  • Demchenko YN, Kuehl WM. 2010. A critical role for the NFκB pathway in multiple myeloma. Oncotarget. 1:59–68.
  • El Bouzidi L, Larhsini M, Markouk M, Abbad A, Hassani L, Bekkouche K. 2011. Antioxidant and antimicrobial activities of Withania frutescens. Nat Prod Commun. 6:1447–1450.
  • Erazo S, Rocco G, Zaldivar M, Delporte C, Backhouse N, Castro C, Belmonte E, Monache FD, Garcia R. 2008. Active metabolites from Dunalia spinosa resinous exudates. Z Naturforsch C J Biosci. 63:492–496.
  • Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. 2017. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 31:1915–1921.
  • Gonzalez AG, Darias V, Martin H, Suarez MC. 1982. Cytostatic activity of natural withanolides from Spanish Withania. Fitoterapia. 53:85–88.
  • Hang H, Samadi AK, Cohen MS, Timmermann BN. 2012. Antiproliferative withanolides from the Solanaceae: a structure–activity study. Pure Appl Chem. 84:1353–1367.
  • Hepper FN. 1991. Old World Withania (Solanaceae): A taxonomic review and key to the species. In: Hawkes JG, Lester RN, Nee M, Estrada N, editors. Solanaceae III taxonomy, chemistry, evolution. Richmond: The Royal Botanic Gardens Kew, p. 211–227.
  • Heyninck K, Lahtela-Kakkonen M, Van der Veken P, Haegeman G, Vanden Berghe W. 2014. Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ. Biochem Pharmacol. 91:501–509.
  • Issa ME, Cuendet M. 2017. Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells. Med Chem Commun. 8:112–121.
  • Jayaprakasam B, Nair MG. 2003. Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron. 59:841–849.
  • Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. 2003. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 74:125–132.
  • Khan PM, Nawaz HR, Ahmad S, Malik A. 1999. Ajugins C and D, new withanolides from Ajuga parviflora. Helv Chim Acta. 82:1423–1426.
  • Lavie D, Glotter E, Shvo Y. 1965. Constituents of Withania somnifera-III-the side chain of withaferin A. J Org Chem. 30:1774–1778.
  • Llanos GG, Araujo LM, Jiménez IA, Moujir LM, Vázquez JT, Bazzocchi IL. 2010. Withanolides from Withania aristata and their cytotoxic activity. Steroids. 75:974–981.
  • Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T. 2006. Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol. 105:336–341.
  • Mesaik MA, Zaheer-ul-Haq, Murad S, Ismail Z, Abdullah NR, Gill HK, Atta-ur-Rahman, Yousaf M, Siddiqui RA, Ahmad A, et al. 2006. Biological and molecular docking studies on coagulin-H: Human IL-2 novel natural inhibitor. Mol Immunol. 43:1855–1863.
  • Ndongo JT, Ngo Mbing J, Feussi Tala M, Monteillier A, Pegnyemb DE, Cuendet M, Laatsch H. 2017. Indoline alkaloids from Tabernaemontana contorta with cancer chemopreventive activity. Phytochemistry. 144:189–196.
  • Neogi P, Kawai M, Butsugan Y, Mori Y, Suzuki M. 1988. Withacoagin, a new withanolide from Withania coagulans roots. Bull Chem Soc Jpn. 61:4479–4481.
  • Şahin F, Güllüce M, Daferera D, Sökmen A, Sökmen M, Polissiou M, Agar G, Özer H. 2004. Biological activities of the essential oils and methanol extract of Origanum vulgare ssp. vulgare in the Eastern Anatolia region of Turkey. Food Control. 15:549–557.
  • The Plant List. 2013. Version 1.1. Published on the Internet. [accessed 2018 Mar 27]. http://www.theplantlist.org/.
  • Zhang H, Timmermann BN. 2016. Withanolide structural revisions by 13C NMR spectroscopic analysis inclusive of the γ-gauche effect. J Nat Prod. 79:732–742.